Amneal Pharmaceuticals (AMRX) Gains FDA Nod As Fair Value Sits Higher

FDA approval that moved Amneal Pharmaceuticals stock

Amneal Pharmaceuticals (AMRX) drew fresh investor attention after the FDA cleared its generic lanreotide injection with Competitive Generic Therapy status, targeting a reference drug market with US$983 million in annual U.S. sales.

For context, Amneal Pharmaceuticals shares eased 0.87% in the latest session to US$19.33 after a sharp reaction to the lanreotide news. Yet the stock still carries a 52.69% year to date share price return and a 1 year total shareholder return of 99.07%, with multi year total shareholder returns in the hundreds of percent, which hints that investor momentum has been building rather than fading.

Capitalize on the momentum around Amneal Pharmaceuticals by scanning a curated 16 high quality undiscovered gems that could be setting up for their own catalyst driven rerating.

After a sharp FDA driven surge and a long stretch of strong returns, is Amneal Pharmaceuticals still offering an attractive risk reward trade off at around US$19, or has the easy money already been made?

Most Popular Narrative: 12% Undervalued

Against the last close at $19.33, the most followed narrative for Amneal Pharmaceuticals points to a fair value of $22, which frames today’s FDA catalyst inside a much bigger story about generics scale, specialty products and biosimilars.

Amneal is well positioned to benefit from the global rise in chronic diseases and an aging population, as evidenced by its methodical diversification into branded and complex products and its active pipeline of 20-30 new annual launches (including biosimilars and injectables). This should drive sustained higher revenue over the long term as demand for affordable and essential medications continues to increase.

See why 18 investors see Amneal Pharmaceuticals as 12% undervalued.

Result: Fair Value of $22 (UNDERVALUED)

Still, the Amneal Pharmaceuticals story can fray quickly if U.S. generics pricing pressure bites harder than expected or if debt keeps limiting investment firepower.

Find out about the key risks to this Amneal Pharmaceuticals narrative.

Another angle on Amneal Pharmaceuticals valuation

On simple earnings multiples, Amneal Pharmaceuticals looks much less forgiving. The stock trades on a P/E of 42.8x, compared with 16.4x for the wider US Pharmaceuticals group and 18.9x for close peers, while the fair ratio points closer to 26.9x. That gap loads more valuation risk onto any future stumble, so how comfortable are you paying this kind of premium for the current pace of execution?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Curious whether the mix of enthusiasm and caution around Amneal Pharmaceuticals matches your own read of the situation? Move fast, stress test the thesis from both angles, and weigh up the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Amneal Pharmaceuticals?

Do not stop with Amneal Pharmaceuticals when the same tools can surface other potential opportunities that fit your style, risk comfort and income needs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com